SCHEMBL22650344

SCHEMBL22650344

CC(C)(C)OC(=O)N1CCN(c2cccc(N)c2)C(=O)C1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.53
USP30 Q70CQ3 2/20 0.47
GPR119 Q8TDV5 3/20 0.46
P2RX7 Q99572 1/20 0.44
ESR2 Q92731 1/20 0.43
MAPT P10636 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
SMARCA2 P51531 1/20 0.40
SMARCA4 P51532 1/20 0.40
PBRM1 Q86U86 1/20 0.40
PDK2 Q15119 1/20 0.40
ADORA1 P30542 1/20 0.40
NAMPT P43490 1/20 0.39
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30998085 1.00 NR1H2 (0.53) NR1H2USP30GPR119P2RX7ESR2
SCHEMBL5891913 0.88 P2RX7 (0.58) NR1H2USP30GPR119P2RX7ESR2
SCHEMBL19690382 0.87 USP30 (0.45) NR1H2USP30GPR119P2RX7ESR2
SCHEMBL1583541 0.87 HPGDS (0.48) NR1H2USP30GPR119P2RX7
SCHEMBL3068738 0.86 GPR119 (0.53) NR1H2USP30GPR119ESR2MAPT
SCHEMBL76458 0.85 NR1H2 (0.54) NR1H2GPR119ESR2MAPTALDH1A1
SCHEMBL30998103 0.84 MAPT (0.55) NR1H2USP30MAPTALDH1A1LMNA
SCHEMBL6982296 0.84 LIPE (0.47) NR1H2USP30GPR119P2RX7ESR2
SCHEMBL1583449 0.84 GRM5 (0.46) NR1H2USP30GPR119P2RX7MAPK1
SCHEMBL5119617 0.84 MAPT (0.55) NR1H2USP30MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250129074-A1 CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2025-04-24 US disclosed
EP-4438603-A1 CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2024-10-02 EP disclosed
CN-118234726-A Chimeric compound for androgen receptor protein targeted degradation, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-06-21 CN disclosed
WO-2023093845-A1 CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2023-06-01 WO disclosed
WO-2023093845-A1 CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 江苏恒瑞医药股份有限公司 2023-06-01 WO disclosed
WO-2020224568-A1 CDK INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2020-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129074-A1 CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF AR, NR5A1, CYP17A1 NR1H2 34/4885USP30 2399/4885GPR119 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.